Skip to content
Head to head

Vera Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: VERA · VRTX

Updated moments ago

1-year performance, rebased to 100

VERA -13.6%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
VERAVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price25.45515.02
Change today-4.86%-1.08%
1-year return-8.7%+22.0%
Market cap$1.84B$130.58B
52-week range25.08 – 56.05412.27 – 568.67
Valuation
P/E (TTM)-4.3133.14
P/E percentile, own 5-yr range78th99th
P/B5.526.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-4.6615.32
Net profit (TTM)$-336.91M$3.88B
Revenue (TTM)$10.28M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin-4160.1%33.1%
Net margin-4041.2%30.7%
Free cash flow (TTM)$-376.72M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership117.1%96.8%
Insider activity (12mo)31 buy / 16 sell28 buy / 22 sell
Short interest (% of float)16.8%1.9%
Analyst consensus83% buy / 17% hold (12)95% buy / 5% hold (21)
Analyst price target$70 (+176%)$624 (+21%)
StockVane view
StockVane Quant RatingD (28)C (68)
Company
Employees2496,400
Founded20161989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.